- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04657055
AcQBlate Force Sensing Ablation System EU Study for Atrial Flutter (AcQForce Flutter-EU) (AFL-EU)
February 6, 2023 updated by: Acutus Medical
The Acutus Medical AcQForce Flutter-EU clinical study is a prospective, multi-center, non-randomized global study designed to confirm the safety and effectiveness of the AcQBlate Force Sensing Ablation System in the ablation management of symptomatic cavotricuspid isthmus dependent atrial flutter.
The AcQForce Flutter-EU study is a post-market study that will be run in parallel with a US IDE study of similar design.
Data will be combined to support a pre-market approval (PMA) application to the US Food and Drug Administration (FDA).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jerald Cox, PA
- Phone Number: 762-529-6310
- Email: jerry.cox@acutus.com
Study Contact Backup
- Name: Victoria Low, BS
- Phone Number: 858-472-6577
- Email: victoria.low@acutus.com
Study Locations
-
-
-
Antwerp, Belgium, 2020
- ZNA Middelheim
-
Hasselt, Belgium, 3500
- Jessa Ziekenhuis
-
-
-
-
-
Middlesbrough, United Kingdom, TS4 3BW
- James Cook University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects are clinically indicated for de novo catheter ablation of typical atrial flutter.
- At least one (1) documented episode of typical atrial flutter within 180 days (6 months) prior to enrollment, documented by 12-lead ECG.
- Age 18 years or older at time of consent.
- Subjects are willing and able to provide written informed consent to participate in the study and agree to comply with all follow-up visits and evaluations.
Exclusion Criteria:
- In the opinion of the Investigator, any contraindication to the planned atrial ablation, including contraindications to anticoagulation therapy and any other significant uncontrolled or unstable medical condition (e.g. sepsis, acute metabolic illness, chronic kidney disease).
- Inability to entrain CTI dependent AFL by standard pacing at procedure.
- Any prior right atrial cavotricuspid isthmus ablation.
- Any cardiac ablation for non-atrial flutter arrhythmias within 90 days prior to enrollment.
- Any patient scheduled or anticipating an AF ablation within the follow-up period.
- Use of amiodarone within 120 days prior to procedure.
- Cardiac surgery within 60 days prior to enrollment.
- ST-elevation myocardial infarction (STEMI) within 60 days prior to enrollment
- Current unstable angina.
- Documented atrial or ventricular tumors, clots, thrombus, within 30-days prior to enrollment.
- Any history of a known hematologic disorder (bleeding/clotting).
- Implantation of permanent leads of an implantable device in or through the right atrium within 90-days prior to enrollment.
- Subjects with New York Heart Association (NYHA) Class IV heart failure within 6-months prior to enrollment.
- Subjects with an ejection fraction less than 30% within 90 days of enrollment.
- Percutaneous Transluminal Coronary Angioplasty (PTCA) within 30-days of enrollment.
- Clinically significant structural heart disease (including moderate to severe tricuspid valve regurgitation, tricuspid valve stenosis, or tricuspid valve replacement; Ebstein's anomaly, or other congenital heart disease) that would preclude catheter introduction and placement, as determined by the Investigator.
- Any cerebral ischemic/infarct event (excluding transient ischemic attacks) within 180 days prior to enrollment.
- Body Mass Index (BMI) >42 kg/m2.
- International Normalized Ratio (INR) > 3.
- Severe uncontrolled systemic hypertension (systolic pressure > 240 mm Hg) within the last 30-days.
- Women who are pregnant or plan to become pregnant within the course of their participation in the investigation.
- Current enrollment in any other study protocol where testing or results from the study may interfere with the procedure or outcome measurements for this study.
- Any other condition that, in the judgment of the Investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Non-randomized
All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
|
Percutaneous catheter ablation of the cavotricuspid isthmus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects free from procedure/device related Serious Adverse Events (SAEs)
Time Frame: 7 days
|
Subjects free from a composite list of pre-specified procedure/device related Serious Adverse Events (SAEs)
|
7 days
|
Subjects achieving acute procedural success
Time Frame: 20 minutes post ablation
|
Acute procedural success is defined as the demonstration of bidirectional cavotricuspid isthmus block at least 20 minutes following the last radiofrequency application at the cavotricuspid isthmus with the investigational System.
|
20 minutes post ablation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: James Daubert, MD, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 23, 2021
Primary Completion (ACTUAL)
May 12, 2022
Study Completion (ACTUAL)
June 12, 2022
Study Registration Dates
First Submitted
December 1, 2020
First Submitted That Met QC Criteria
December 1, 2020
First Posted (ACTUAL)
December 8, 2020
Study Record Updates
Last Update Posted (ESTIMATE)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 6, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP-21-EU (Other Identifier: Acutus Medical, Inc.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Typical Atrial Flutter
-
Liverpool Heart and Chest Hospital NHS Foundation...Medtronic International Trading SarlCompletedAtrial Flutter TypicalUnited Kingdom, Switzerland
-
Ospedale San FrancescoUnknownTypical Atrial FlutterItaly
-
University of PennsylvaniaWithdrawnTypical Atrial Flutter | Risk Factors With Future Development of Atrial FlutterUnited States
-
Hangzhou Dinova EP Technology Co., LtdNot yet recruiting
-
University of ManchesterManchester University NHS Foundation TrustWithdrawn
-
Abbott Medical DevicesCompletedTypical Atrial FlutterUnited States, Canada
-
Abbott Medical DevicesCompletedTypical Atrial FlutterUnited States, Canada
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Imricor Medical SystemsNot yet recruitingAtrial Flutter Typical
-
Imperial College Healthcare NHS TrustAbbottRecruitingAtrial Flutter TypicalUnited Kingdom
Clinical Trials on The AcQBlate® Force Sensing Ablation System
-
Acutus MedicalCompletedTypical Atrial FlutterBelgium, United States, United Kingdom
-
Acutus MedicalNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Acutus MedicalWithdrawnParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Acutus MedicalWithdrawn
-
Erasmus Medical CenterUnknownTachycardia, Supraventricular | Tachycardia; Paroxysmal, SupraventricularNetherlands
-
Ningbo No. 1 HospitalCompletedParoxysmal Supraventricular TachycardiaChina
-
Shanghai MicroPort EP MedTech Co., Ltd.Active, not recruitingParoxysmal Supraventricular TachycardiaChina
-
Abbott Medical DevicesEndosenseCompletedAtrial Fibrillation | Tachycardia, Supraventricular
-
Medtronic - MITGCompletedHIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial LesionsUnited States
-
Hangzhou Broncus Medical Co., Ltd.Shanghai Chest HospitalRecruitingStage IA Lung CancerChina